Growth Hormone Treatment for Severe Fibromyalgia
Author Information
Author(s): Cuatrecasas Guillem, Riudavets Cristina, Güell Maria Antònia, Nadal Albert
Primary Institution: Centro Médico Teknon, Barcelona, Spain
Hypothesis
Does adding low dose growth hormone to standard therapy improve outcomes in fibromyalgia patients with low IGF-1 levels?
Conclusion
Adding a daily dose of growth hormone to standard therapy significantly reduces tender points and improves quality of life in severe fibromyalgia patients with low IGF-1 levels.
Supporting Evidence
- The GH group showed a 60% reduction in tender points compared to the control group.
- Significant improvements were observed in the Fibromyalgia Impact Questionnaire and EQ-VAS scores.
- Most patients in the GH group experienced improvement within the first months.
Takeaway
This study found that giving growth hormone to people with severe fibromyalgia and low IGF-1 levels helped reduce their pain and improve their quality of life.
Methodology
A randomized, open-label, controlled trial with 24 patients receiving either growth hormone or standard therapy for one year.
Potential Biases
Potential bias due to the open-label design.
Limitations
The study lacked a placebo group and had a small sample size.
Participant Demographics
All participants were women with a mean age of 48.5 years.
Statistical Information
P-Value
p < 0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website